BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31239713)

  • 1. Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells.
    Cui L; Liu M; Lai S; Hou H; Diao T; Zhang D; Wang M; Zhang Y; Wang J
    Onco Targets Ther; 2019; 12():4451-4459. PubMed ID: 31239713
    [No Abstract]   [Full Text] [Related]  

  • 2. Palmitoylome profiling indicates that androgens regulate the palmitoylation of α‑tubulin in prostate cancer‑derived LNCaP cells and supernatants.
    Li W; Zhang J; Zou L; Cui J; Su F; Jin J; Xiao F; Liu M; Zhao G
    Oncol Rep; 2019 Dec; 42(6):2788-2796. PubMed ID: 31578588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Palmitoylome profiling indicates that androgens promote the palmitoylation of metabolism-related proteins in prostate cancer-derived LNCaP cells].
    Li WQ; Ren SM; Long XB; Tian YQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):227-233. PubMed ID: 32306003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.
    Khurana N; Chandra PK; Kim H; Abdel-Mageed AB; Mondal D; Sikka SC
    Antioxidants (Basel); 2020 Jan; 9(1):. PubMed ID: 31940946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells.
    Izumi K; Mizokami A
    J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30871130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY; Dong Q; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status.
    Kavya K; Kumar MN; Patil RH; Hegde SM; Kiran Kumar KM; Nagesh R; Babu RL; Ramesh GT; Chidananda Sharma S
    Mol Cell Biochem; 2017 Sep; 433(1-2):13-26. PubMed ID: 28386843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Androgen Receptor in Prostate Cancer: A Review.
    Fujita K; Nonomura N
    World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.